Navigation Links
Boston Scientific Announces Release of Next-Generation iLab(R) System Software

NATICK, Mass., Sept. 21 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced release of its CE-Marked, next-generation iLab System Software for the iLab(R) Ultrasound Imaging System. Intravascular Ultrasound (IVUS) technology is designed to provide physicians a 360-degree view inside the heart and coronary vessels to assist with diagnosis and to allow a more accurate representation of the diseased vessels than is possible with angiography alone. The iLab software upgrade includes functionality designed to improve diagnosis and save time. The principal new feature of the system, iMap(TM), provides a detailed color analysis of plaque composition within the targeted areas.

"The upgraded iLab software, featuring iMap tissue characterization, offers detailed plaque information that may help physicians treat coronary artery disease," said Prof. Patrick W. Serruys, M.D., Ph.D., Chief of Interventional Cardiology, Thoraxcenter-Erasmus University, Rotterdam. "The combination of Boston Scientific's 40MHz catheter and the new characterization algorithm represents the latest generation of IVUS imaging technology."

In addition to iMap, the iLab software includes features such as Modality Worklist Management, which allows a physician to access a patient's profile from the hospital server and view it on the iLab System monitor. Additional features include an on-screen print icon and the ability to edit and save video images of a procedure directly to CD, DVD or hard drive. The iLab software is currently in a global limited market release with full commercial availability planned for later this year in all regions.

iMap software is not currently approved for sale in the U.S.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit:

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding regulatory approvals, product performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

    CONTACT:  Paul Donovan
              508-650-8541 (office)
              508-667-5165 (mobile)
              Media Relations
              Boston Scientific Corporation

              Larry Neumann
              508-650-8696 (office)
              Investor Relations
              Boston Scientific Corporation

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Boston Scientific Amends Credit Facility and Prepays $1 Billion on Loan
4. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
5. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
6. Boston Scientific Announces Election of Ray Elliott to Its Board of Directors
7. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
8. Boston Scientific Releases Remote Monitoring Data from its Wireless LATITUDE(R) Patient Management System
9. Genzyme Begins Major Expansion of Boston Manufacturing Facility
10. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
11. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
Post Your Comments:
(Date:10/8/2015)...  The ALS Association, in partnership with Prize4Life, is ... revolutionize communication technology solutions for people living with ALS. ... (amyotrophic lateral sclerosis) is a progressive neurodegenerative disease that ... spinal cord. Eventually, people with ALS lose the ability ... to total paralysis and death within two to five ...
(Date:10/8/2015)... ... ... Talon Innovations, a provider of Precision Machined Products and Assemblies ... one of three finalists for the Minnesota Business magazine’s Manufacturing Award in the category ... was recognized as a nominee for this competitive award. , The “Best in ...
(Date:10/7/2015)... , Oct. 7, 2015 Boston ... the start of the Boston Scientific Connected Patient ... advancements in the use of remote patient monitoring to ... designers and entrepreneurs can submit their ideas and collaborate ... ( ). Cambridge, MA ...
(Date:10/7/2015)... -- ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV ) ("ContraVir" or ... and commercialization of targeted antiviral therapies, today announced the ... of its common stock and warrants to purchase up ... a fixed combined price to the public of $3.00. ... issued separately.  The warrants will be exercisable for a ...
Breaking Biology Technology:
... , , HUNTSVILLE, Ala., ... in nucleic acid therapeutics and delivery, announced today that Jason ... Pharmacology to Vice-President of Preclinical Research and Development. , ... management and scientific leadership experience in the biotechnology industry and ...
... , , SAN MARINO, Calif., ... has formed a wholly owned subsidiary called MetaCytoLytics, Inc. This ... of Colorado Professor M. Karen Newell called "metabolic disruption technology" ... generate energy from glucose or from fatty acids. That ...
... , , PASADENA, Calif., Aug. 6 AutoImmune ... $86,000, or $0.01 per share basic and diluted, for the three ... $86,000, or $0.01 per share basic and diluted, for the three ... 30, 2009, the net loss was $256,000, or $0.02 per share ...
Cached Biology Technology:
(Date:9/10/2015)... 10, 2015 Report Details ... Selling Opportunities and Revenue Prospects to Help You ... biologics, especially new drug classes? Get the latest ... with exclusive market data and industry knowledge, benefitting ... results, opportunities and sales predictions. Visiongain,s new ...
(Date:9/9/2015)... , Sept. 9, 2015  NuData Security ... and solution-based milestones, furthering the company,s commitment to ... online fraud. NuData Security,s online fraud ... the company,s growth cycle. The product combines continual ... determine good user behavior from fraudulent behavior, allowing ...
(Date:9/2/2015)... 2015 Security of data and assets ... government organizations, telecommunications, hospitals, as well as individuals. ... being used to prevent unauthorised access. Technological advancements ... individuals could gain access to secure premises after ... hardware devices and numeric codes. However, hackers also ...
Breaking Biology News(10 mins):
... for Medical Research have glimpsed two proteins working together ... nucleus and its exterior compartment, the cytoplasm. The research ... is found in organisms from yeast to humans does ... Investigator Sue Jaspersen, Ph.D., focused on a protein called ...
... at high elevations found in residents of the Tibetan ... related to contemporary Sherpa. These genes were passed on ... mixing, and then amplified by natural selection in the ... by scientists from the University of Chicago and Case ...
... that electrically stimulate the auditory nerve have granted ... people worldwide who otherwise would be totally deaf. Existing ... transmitter about an inch in diameter be affixed to ... joint microphone and power source that looks like an ...
Cached Biology News:
Mouse monoclonal [050-04] to C2 ( Abpromise for all tested applications). entrezGeneID: 717 SwissProtID: P06681...
Reacts with methylated DNA from plants and vertebrates...
Rabbit polyclonal to Bag5 ( Abpromise for all tested applications). entrezGeneID: 9529 SwissProtID: Q9UL15...
Biology Products: